---
title: "Glucotrack (GCTK) news: reverse split, delisting and offering"
url: "https://aibio.space/companies/glucotrack/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "GCTK reverse split, delisting, offering, convertible notes and merger news: Glucotrack effects 1-for-15 reverse stock split. Glucotrack, Inc."
---

GCTK Glucotrack, Inc. NASDAQ · United States

# Glucotrack (GCTK) news GCTK reverse split, delisting and offering news

Listings · 2026-10-28

## [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Nasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at the open on October 30, 2026.

## Latest Glucotrack news

1. 2026-10-22 Debt Financing [Glucotrack sells secured convertible notes and warrants, with Dawson James as placement agent](https://aibio.space/news/glucotrack-sells-secured-convertible-notes-warrants-dawson-james/) The senior secured convertible notes carry a 22% original issue discount, 8% interest and a 9-month term. Dawson James Securities, Inc. is named as placement agent.
2. 2026-09-28 Debt Financing [Glucotrack amends terms of senior secured convertible note](https://aibio.space/news/glucotrack-amends-terms-senior-secured-convertible-note/) The amendment makes the floor price a hard limit and requires any make-whole payment to be made in cash. Glucotrack had $1.1 million in cash and cash equivalents at June 30, 2026.
3. 2026-09-23 Mergers [Glucotrack CEO outlines Lokahi priorities for LT-100 and the ai² platform](https://aibio.space/news/glucotrack-ceo-outlines-lokahi-priorities-lt-100-ai2-platform/) In a strategic update dated September 23, 2026, Glucotrack and Lokahi Therapeutics said LT-100 is the immediate priority, with a clinical protocol submitted for regulatory review.
4. 2026-09-14 Company Updates [Glucotrack director resigns, citing possible conflict over merger terms](https://aibio.space/news/glucotrack-director-resigns-citing-possible-conflict-merger-terms/) Director Paul V. Goode resigned effective immediately after notifying the board on September 14, 2026, saying the merger agreement with Lokahi Therapeutics, Inc. could create a conflict of interest between the company and its subsidiary.
5. 2026-09-11 Debt Financing [Glucotrack issues secured convertible notes and warrants in private placement](https://aibio.space/news/glucotrack-issues-secured-convertible-notes-warrants-private-placement/) The nine-month notes carry 8% interest and a 22% original issue discount, with Dawson James Securities, Inc. as placement agent and an exchange cap of 19.99%.
6. 2026-08-28 Listings [Glucotrack effects 1-for-15 reverse stock split](https://aibio.space/news/glucotrack-effects-1-15-reverse-stock-split/) The reverse split took effect August 28, 2026, with trading on a split-adjusted basis from August 31, 2026, and shares outstanding were reduced from 11,972,157 to approximately 798,144.
7. 2026-08-07 Financings [Glucotrack amends White Lion equity line with commitment shares](https://aibio.space/news/glucotrack-amends-white-lion-equity-line-commitment-shares/) Glucotrack amended its July 14, 2026 common stock purchase agreement with White Lion Capital, LLC, agreeing to issue 2,505,513 commitment shares and to pay a true-up amount if the commitment fee price falls below the minimum price.
8. 2026-08-04 Debt Financing [Glucotrack adds $3,500,000 to secured convertible bridge financing](https://aibio.space/news/glucotrack-adds-3-500-000-secured-convertible-bridge-financing/) Glucotrack issued follow-on senior secured convertible notes with a $4,487,179 face amount and sold pre-funded warrants in an interim private placement.
9. 2026-07-29 Company Updates [Glucotrack unit advances LT-100 toward single-injection dosing](https://aibio.space/news/glucotrack-unit-advances-lt-100-toward-single-injection-dosing/) Lokahi Therapeutics, a wholly owned subsidiary of Glucotrack, said nonclinical results support testing one subcutaneous injection in place of up to 15 intradermal injections, with clinical evaluation possibly starting in the fourth quarter of 2026.

## Glucotrack at a glance

- **Ticker**: GCTK

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $1.1 million

### Related companies

- [VITASPRING BIOMEDICAL CO. LTD.](https://aibio.space/companies/vitaspring-biomedical/) OTC: VSBC
- [ACCURAY INC](https://aibio.space/companies/accuray/) NASDAQ: ARAY
- [LABCORP HOLDINGS INC.](https://aibio.space/companies/labcorp/) NYSE: LH
- [AIBOTICS, INC.](https://aibio.space/companies/aibotics/) OTC: AIBT
- [Edwards Lifesciences](https://aibio.space/companies/edwards-lifesciences/) NYSE: EW
- [USANA HEALTH SCIENCES INC](https://aibio.space/companies/usana-health-sciences/) NYSE: USNA
- [ZIMMER BIOMET HOLDINGS, INC.](https://aibio.space/companies/zimmer-biomet/) NYSE: ZBH
- [Hongchang International Co.](https://aibio.space/companies/hongchang-international/) OTC: HCIL

### Also on NASDAQ

- [MARAVAI LIFESCIENCES HOLDINGS, INC.](https://aibio.space/companies/maravai-lifesciences/) MRVI
- [electroCore](https://aibio.space/companies/electrocore/) ECOR
- [Ocugen](https://aibio.space/companies/ocugen/) OCGN
- [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) AMPH
- [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) REGN
- [NovoCure](https://aibio.space/companies/novocure/) NVCR

## Glucotrack annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$9.8 million](https://www.sec.gov/Archives/edgar/data/1506983/000149315226013656/) | [$9.5 million](https://www.sec.gov/Archives/edgar/data/1506983/000149315226013656/) |
| Net income (loss) | [-$19.4 million](https://www.sec.gov/Archives/edgar/data/1506983/000149315226013656/) | [-$22.6 million](https://www.sec.gov/Archives/edgar/data/1506983/000149315226013656/) |
| Cash from operations | [-$15.2 million](https://www.sec.gov/Archives/edgar/data/1506983/000149315226013656/) | [-$12.5 million](https://www.sec.gov/Archives/edgar/data/1506983/000149315226013656/) |
| Cash and equivalents | [$7.4 million](https://www.sec.gov/Archives/edgar/data/1506983/000149315226038317/) | [$5.6 million](https://www.sec.gov/Archives/edgar/data/1506983/000149315226013656/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.1 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Glucotrack

Did Glucotrack do a reverse stock split?

Our latest story on this, dated Aug 28, 2026: "Glucotrack effects 1-for-15 reverse stock split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/glucotrack-effects-1-15-reverse-stock-split/).

Was Glucotrack delisted?

Our latest story on this, dated Oct 28, 2026: "Nasdaq to delist Glucotrack shares after bid price exception ends". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/).

Has Glucotrack raised money recently?

Our latest story on this, dated Sep 11, 2026: "Glucotrack issues secured convertible notes and warrants in private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/glucotrack-issues-secured-convertible-notes-warrants-private-placement/).

Has Glucotrack sold convertible notes?

Our latest story on this, dated Oct 22, 2026: "Glucotrack sells secured convertible notes and warrants, with Dawson James as placement agent". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/glucotrack-sells-secured-convertible-notes-warrants-dawson-james/).

Is Glucotrack involved in a merger or acquisition?

Our latest story on this, dated Sep 14, 2026: "Glucotrack director resigns, citing possible conflict over merger terms". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/glucotrack-director-resigns-citing-possible-conflict-merger-terms/).

What is the ticker symbol of Glucotrack?

Glucotrack, Inc. trades under the ticker GCTK on NASDAQ.

Where is Glucotrack listed?

Glucotrack, Inc. is listed on NASDAQ.

Which country or territory is Glucotrack listed under?

Our directory records Glucotrack, Inc. under United States.

Does aibio.space cover Glucotrack?

aibio.space lists Glucotrack, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Glucotrack profitable?

Glucotrack, Inc. reported a net loss of $19.4 million for the fiscal year ended Dec 31, 2025, and used $15.2 million of cash in operations, per its annual report to the SEC.

How much does Glucotrack spend on research and development?

$9.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Glucotrack have?

$1.1 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Glucotrack (GCTK) stock news?

Our latest story on Glucotrack, dated Oct 28, 2026: "Nasdaq to delist Glucotrack shares after bid price exception ends". Nasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at the open on October 30, 2026. [Source](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/).

How can I follow Glucotrack (GCTK) news?

Press Follow on this page to add Glucotrack to your Following list, or subscribe to the aibio.space newsletter. We have published 10 stories naming Glucotrack so far, in Company Updates, Debt Financing, Financings, Listings, Mergers.

## Investor discussion: Glucotrack

Members talk about Glucotrack (GCTK). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Glucotrack, newest first. Each line links the filing it comes from.

1. 2026-10-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226049299/form8-k.htm)
2. 2026-10-28 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226048981/ex99-1.htm)
3. 2026-10-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226047582/form8-k.htm)
4. 2026-10-13 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226046851/formpre14a.htm)
5. 2026-08-28 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226040653/form8-k.htm)
6. 2026-08-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226040332/ex99-1.htm)
7. 2026-08-19 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226039143/form8-k.htm)
8. 2026-08-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226038317/form10-q.htm)
9. 2026-08-10 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226036858/form8-k.htm)
10. 2026-07-17 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226033763/formdef14a.htm)
11. 2026-07-15 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,5.01,5.02,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226033393/ex99-1.htm)
12. 2026-06-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226029111/formpre14a.htm)
13. 2026-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506983/000149315226023889/form8-k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GCTK on TradingView](https://www.tradingview.com/symbols/NASDAQ-GCTK/).

## Listing details

Glucotrack, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GCTK, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Glucotrack, Inc.

- **Ticker**: GCTK

- **Listing**: NASDAQ

- **Country or territory**: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/glucotrack/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Glucotrack (GCTK) news: reverse split, delisting and offering", 2026-10-31, https://aibio.space/companies/glucotrack/